Search results
This finding has prompted consideration of GLP-1 receptor agonists as potential weight-loss agents . Indeed, liraglutide 3.0 mg day −1 was approved for weight management in the US on December 23, 2014 , and in the EU on March 23, 2015. The mechanisms by which GLP-1 receptor agonists mediate weight loss are not yet fully understood.
- GLP-1 Agonists for Weight Loss: Pharmacology and Clinical ... - PubMed
Additionally, we review the evidence of four recent clinical...
- GLP-1 Agonists for Weight Loss: Pharmacology and Clinical ... - PubMed
6 cze 2023 · GLP‐1 RAs have also been shown to be effective for weight management and maintenance of weight loss in the treatment of people with overweight or obesity . Because absolute weight losses are greater for individuals without diabetes, trials included individuals with obesity, both with and without T2D.
In this real-world cohort of over 2,400 patients with type 2 diabetes (baseline BMI 37 kg/m 2, HbA1c 8.5%), we found that initiation of a GLP-1 agonist (predominantly dulaglutide or liraglutide) without a structured behavioral intervention was associated with a 2% (~6 lbs) weight loss at 72 weeks.
1 paź 2022 · Our meta-regression showed that trials in non-T2DM participants compared to trials in participants with T2DM demonstrated 2.47 kg (95% CI, 0.82 to 4.12) greater weight loss than placebo, indicating that diabetes status is an independent predictor of efficacy of GLP-1 receptor agonists on weight loss (R 2 = 0.67, tau 2 = 1.635, I 2 = 0.84), and ...
The benefit of Glucagon-like Peptide-1 (GLP-1) receptor agonists (RAs) in weight reduction against potential harms remains unclear. This study aimed at evaluating the benefit-harm balance of initiating GLP-1 RAs versus placebo for weight loss in people living with overweight and obesity but without diabetes.
Additionally, we review the evidence of four recent clinical trials, two systematic reviews, and two meta-analyses describing the efficacy of GLP-1 agonists in decreasing weight, lowering HbA1c, and improving obesity comorbidities.
Purpose: This study aimed to provide evidence-based support and a reference for the efficacy and safety of seven glucagon-like peptide-1 (GLP-1) receptor agonists and polyagonists for weight loss in patients with obesity or overweight through a network meta-analysis.
